<DOC>
	<DOCNO>NCT01849133</DOCNO>
	<brief_summary>The purpose study investigate efficacy exclusive intraoperative radiation therapy conserve surgery early-stage breast cancer compare whole breast radiotherapy . The primary outcome rate ipsilateral true recurrence ( recurrence close primary tumor bed ) new ipsilateral tumor ( recurrence occur quadrant previous one ) recurrence free survival .</brief_summary>
	<brief_title>Randomized Trial Intraoperative Radiotherapy Full Dose Vs External Radiotherapy</brief_title>
	<detailed_description>The ELIOT trial prospective single center randomise phase III trial compare intraoperative radiotherapy electron tumor bed conventional scheme whole breast external beam radiotherapy . Patients randomly allocate intraoperative radiotherapy group external radiotherapy group 1:1 ratio . The rationale provide partial breast irradiation tumor bed lie pattern ipsilateral breast tumor relapse report Literature . In fact , majority recurrence occur close tumor bed . Several randomized trial breast conserve surgery without whole breast radiotherapy show 75-90 % case recurrences site original primary tumor . In context , limit irradiation tumor bed may result similar local control whole breast irradiation , provide patient properly select . The intraoperative treatment deliver mobile miniaturize accelerator , locate operating room , external radiotherapy 6 MV linear accelerator use . The surgical technique perform ELIOT standardize every step . The breast gland prepare separate subcutaneous tissue underlie pectoralis muscle restore continuity surgical breach protect thoracic wall lead aluminium disk optimize deliver dose . The linear accelerator delivers electron variable energy , range 3 9 MeV : proper electron energy choose accord target thickness . Collimation achieve hard-docking system , consist 5 mm thick high- quality polymethyl methacrylate round applicators 4 10 -cm diameter . For radiation protection primary beam stopper mobile 1.5 cm thick lead shield provide . The prescribed dose 21 Gy 90 % isodose . After delivery radiation dose , applicator disk remove gland reconstruct . In conventional arm study , external beam radiotherapy give full recovery surgical excision . All patient undergo virtual simulation include treatment-planning CT scan . The clinical target volume define extend 5 mm skin surface include breast parenchyma deep fascia , include underlying muscle rib cage . The irradiated volume extend medially midline , laterally mid axillary line inferiorly 1-2 cm level intra-mammary fold superiorly suprasternal notch . Using BEV , block use shield much heart lung possible without compromise PTV . Treatment deliver pair tangential field wedge necessary . The prescribed dose whole-breast 50 Gy deliver 2 Gy fraction 5 week 6 -megavolt linear accelerator follow sequential boost 10 Gy tumor bed electron . A PTV dose homogeneity -5 % + 7 % recommend ICRU ( International Commission Radiation Units Measurements ) report 50 . Patients follow least 6-month clinical examination 5 year every 8 month thereafter . Annual mammogram perform .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Age ≥ 48 &lt; 75 Clinical mammographic/ultrasound diagnosis unicentric carcinoma , ultrasound diameter ≤2.5 cm . Advisable , mandatory , execution mammoscintigraphy MDP99mTc ( Methyl diphosphonate technetium99m ) : procedure allow bone stag map eventual multifocality/multicentricity breast neoplasm . No previous therapy ( biopsy include ) breast cancer Institutions . Patients nonpalpable lesion undergo preoperative centering stereotactic and/or ultrasoundguided cytology ( execution last procedure mandatory ) . Adequate information patient inform consent . Ductal lobular noninfiltrating carcinoma . Paget disease . Tumor close proximity skin . Tumor axillary tail . Documented multicentricity/multifocality tumor . Patients underwent excisional biopsy Institutions . Histology different carcinoma . Personal anamnesis positive malignancy ( basocellular carcinoma , situ carcinoma cervix , contralateral breast cancer free disease 15 year followup exclude ) . General contraindication regular followup radiotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>48 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>conservative surgery</keyword>
	<keyword>intraoperative radiation therapy</keyword>
	<keyword>mobile linear accelerator</keyword>
</DOC>